NCT00638794已完成不适用
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents
Cardiovascular Research Foundation, New York8 个研究点 分布在 1 个国家目标入组 8,575 人开始时间: 2008年1月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 8,575
- 试验地点
- 8
- 主要终点
- Definite or probable stent thrombosis using the Academic Research Consortium (ARC) definition, primary events only.
研究概览
简要总结
Prospective, multicenter, registry of at least 11,000 (and up to 15,000) consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.
详细描述
To determine:
- the frequency, timing and correlates (clinical and angiographic) of drug-eluting stent (DES) thrombosis in a patient population with few clinical and angiographic exclusion criteria,
- the relationship of aspirin and/or clopidogrel hyporesponsiveness, and general platelet reactivity to early and late DES thrombosis in separate phases stratified by whether the patient is taking dual (aspirin plus clopidogrel) or single (aspirin alone) antiplatelet therapy, and
- combining the findings from the above 2 objectives, to identify a cohort representing a significant proportion of all patients at increased risk to have early and/or late DES stent thrombosis.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients undergoing PCI in whom at least one DES is implanted and in whom PCI of all treated lesions is successful (diameter stenosis <30% with TIMI 3 flow in all treated lesions) without major complications (defined as freedom from procedural death, intra-procedural stent thrombosis, procedural myocardial infarction or sustained vessel closure, or need for emergency bypass graft surgery). One or more bare metal stents (BMS) may be implanted, and other lesions may be treated without stenting as long as at least one DES is implanted. However, the procedure must be successful and uncomplicated (as defined above) for all lesions (DES + BMS + non-stent).
- •Aspirin use: Adequate aspirin loading given prior to PCI: at least 300 mg non enteric coated oral aspirin at least 1 hour prior to the procedure or 324 mg chewed or 250 mg IV aspirin at least 30 minutes prior to the procedure.
- •Patient has Hematocrit between 30 and 52% and Platelet Count greater than 100,000/µl.
- •For US sites: Only FDA-approved DES stents may be used in this study. For OUS sites: Only DES stents that are CE marked for approval may be used in this study.
- •PCI performed with unfractionated or low molecular weight heparin, or bivalirudin as the procedural antithrombin.
- •Patient or guardian able to provide informed written consent.
排除标准
- •Patients in whom blood for Accumetrics VerifyNow platelet function testing cannot be drawn after the minimum clopidogrel loading duration and Glycoprotein (GP) IIb/IIIa inhibitor washout duration as follows:
- •Clopidogrel loading: Clopidogrel loading pre PCI is recommended, but post PCI clopidogrel loading is acceptable per standard of care. In all patients (whether or not clopidogrel is initiated pre or post PCI), prior to blood drawing for VerifyNow platelet function testing, a 600 mg loading dose must have been given at least 6 hours prior, or a 300 mg loading dose must have been given at least 12 hours prior, or the patient must have been maintained on at least 75 mg of clopidogrel daily for at least 5 days.
- •GP IIb/IIIa inhibitor washout: Eptifibatide or tirofiban must have been discontinued for at least 24 hours prior to VerifyNow platelet function testing. Abciximab must have been discontinued for at 10 days prior to VerifyNow platelet function testing.
- •Inability of the VerifyNow system to measure either Aspirin, P2Y12 or IIb/IIIa platelet responsiveness.
- •Severe allergy to stainless steel, contrast dye, all anti-thrombin agents (unfractionated and low molecular weight heparin and bivalirudin), aspirin or clopidogrel that cannot be adequately pre-medicated.
- •Concurrent enrollment in another trial that involves an investigational stent, antithrombotic or antiplatelet agent. Patient in other investigational trials that have not reached their primary endpoint may be enrolled in ADAPT-DES as long as the other trials do not involve an investigational stent, antithrombotic or antiplatelet agent and inclusion of such patient will have no effect on the endpoint of either study.
- •Patients in whom bypass graft surgery is planned within 2 years.
- •Patients with stent thrombosis before the performance of pre-discharge VerifyNow platelet function testing.
- •Patients unwilling or unable to complete clinical follow-up for the duration of the study.
结局指标
主要结局
Definite or probable stent thrombosis using the Academic Research Consortium (ARC) definition, primary events only.
时间窗: 30 days, 1 year, 2 year
次要结局
- ARC definite, probable, possible or any stent thrombosis, utilizing primary only and then primary + secondary thromboses; death, MI, recurrent ischemia necessitating repeat target lesion and target vessel intervention and MACE.(1 day, 30 days, 1 year, 2 year)
研究者
研究点 (8)
Loading locations...
相似试验
尚未招募
不适用
Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry StudyVertebral Artery StenosisNCT06683300Beijing Tiantan Hospital520
已完成
4 期
Duration of Dual Anti-Platelet Therapy (DUAL-ACS)Acute Coronary SyndromeCoronary Artery DiseaseNCT03252249University of Edinburgh5,094
Unknown
3 期
Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PADPeripheral Artery DiseaseNCT02798913Federico II University300
已完成
4 期
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)Heart DiseasesSyndrome Heart DiseaseCardiovascular DiseasesArterial Occlusive DiseasesCoronary DiseaseVascular DiseasesAcute Coronary SyndromeArteriosclerosisMyocardial IschemiaCoronary Artery DiseaseNCT04624854Harbin Medical University8,250
撤回
4 期
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic AttackTransient Ischemic AttacksMinor StrokeNCT02144831University of Alberta